Tactile Systems Technology Inc
$ 26.35
1.46%
11 Jun - close price
- Market Cap 594,132,000 USD
- Current Price $ 26.35
- High / Low $ 26.69 / 25.41
- Stock P/E 30.28
- Book Value 9.59
- EPS 0.87
- Next Earning Report 2026-08-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.10 %
- 52 Week High 37.77
- 52 Week Low 9.41
About
Tactile Systems Technology, Inc., a medical technology company, is dedicated to the development and supply of medical devices for chronic diseases in the United States. The company is headquartered in Minneapolis, Minnesota.
Analyst Target Price
$39.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-04 | 2026-02-17 | 2025-11-03 | 2025-08-04 | 2025-05-05 | 2025-02-18 | 2024-11-04 | 2024-08-05 | 2024-05-06 | 2024-02-20 | 2023-11-06 | 2023-08-07 |
| Reported EPS | 0.0024 | 0.46 | 0.36 | 0.14 | -0.11 | 0.397 | 0.25 | 0.2 | -0.05 | 0.35 | 0.85 | 0.04 |
| Estimated EPS | -0.04 | 0.445 | 0.21 | 0.14 | -0.06 | 0.28 | 0.17 | 0.14 | -0.01 | 0.19 | 0.02 | -0.02 |
| Surprise | 0.0424 | 0.015 | 0.15 | 0 | -0.05 | 0.117 | 0.08 | 0.06 | -0.04 | 0.16 | 0.83 | 0.06 |
| Surprise Percentage | 106% | 3.3708% | 71.4286% | 0% | -83.3333% | 41.7857% | 47.0588% | 42.8571% | -400% | 84.2105% | 4150% | 300% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-03 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.17 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TCMD
2026-06-07 03:04:00
This article provides an in-depth analysis of Tactile Systems Technology Inc. (NASDAQ: TCMD), highlighting strong sentiment across all time horizons and an exceptional 81.4:1 risk-reward setup. It details three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, offering specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
2026-06-02 19:10:01
Tactile Medical has launched its next-generation AffloVest high-frequency chest wall oscillation (HFCWO) therapy system, which includes enhancements designed to improve patient comfort, ease of use, and connected care capabilities. The new system is lighter, more adjustable, and features built-in Wi-Fi and Bluetooth connectivity, allowing patients to track progress and clinicians to access real-world data for personalized treatment. It maintains its indication for various chronic neuromuscular and respiratory conditions, aiming to improve therapy adherence and patient experience.
2026-06-02 12:09:55
Tactile Medical has launched its next-generation AffloVest high-frequency chest wall oscillation (HFCWO) therapy system, designed to enhance patient comfort and adherence for those with chronic neuromuscular and respiratory conditions. The updated system features reduced weight, expanded size adjustability, and built-in Wi-Fi and Bluetooth connectivity for improved patient experience and data-driven clinical insights. This innovation aims to provide a more comfortable and connected therapy solution while maintaining clinical effectiveness.
2026-06-02 12:09:55
Tactile Medical has launched its next-generation AffloVest, an airway clearance system designed for patients with chronic neuromuscular and respiratory conditions such as cystic fibrosis and bronchiectasis. The new device is lighter, more adjustable, and includes built-in Wi-Fi and Bluetooth for connected care, aiming to improve patient comfort, ease of use, and therapy adherence. These enhancements also provide clinicians and DME providers with real-world therapy data to support patient care and reimbursement.
2026-06-02 08:00:00
Tactile Medical has launched its next-generation AffloVest high-frequency chest wall oscillation (HFCWO) therapy system, which is designed to improve patient comfort, ease of use, and connectivity. The new system is lighter, more adjustable, and includes built-in Wi-Fi and Bluetooth for tracking progress and sharing data with clinicians. It aims to enhance therapy adherence for individuals with chronic neuromuscular and respiratory conditions such as cystic fibrosis and bronchiectasis.
2026-06-02 07:00:00
Tactile Medical has commercially launched its next-generation AffloVest high-frequency chest wall oscillation (HFCWO) therapy system, ahead of the winter respiratory season. This new system offers enhancements in patient comfort, ease of use, and connected care capabilities, including reduced weight, expanded size adjustability, and built-in Wi-Fi and Bluetooth. The AffloVest aims to improve therapy adherence and provide clinicians with real-world data to support personalized treatment for chronic respiratory conditions like cystic fibrosis and bronchiectasis.
